RIL
FDMT icon

Rothschild Investment LLC’s 4D Molecular Therapeutics FDMT Stock Holding History

Rothschild Investment LLC’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13 Sell
1
-5
-83% -$49 ﹤0.01% 3617
2026
Q1 		$56 Buy
+6
New +$52 ﹤0.01% 3452
2024
Q4 		– Sell
-35
Closed -$378 – 2996
2024
Q3 		$378 Buy
+35
New +$581 ﹤0.01% 2551
2024
Q2 		– Sell
-5
Closed -$159 – 2822
2024
Q1 		$159 Buy
+5
New +$128 ﹤0.01% 1867

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Rothschild Investment LLC's FDMT Position: Q2 2026 in Review

Rothschild Investment LLC reduced its 4D Molecular Therapeutics (FDMT) stake by 83% in Q2 2026, selling an estimated $49 and leaving 1 share worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #3617.

Rothschild Investment LLC first reported a position in FDMT in Q1 2024 and has held it in 4 quarters since. The position peaked at $378 in Q3 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Rothschild Investment LLC held 1 share of 4D Molecular Therapeutics worth $13 as of Q2 2026.
  • Rothschild Investment LLC sold 5 4D Molecular Therapeutics shares in Q2 2026, an estimated $49.
  • 4D Molecular Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3617 holding.
  • Rothschild Investment LLC first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Rothschild Investment LLC's 4D Molecular Therapeutics position peaked at $378 in Q3 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.